MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.

B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.

B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.

B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.

AY 9944 is a potent and specific inhibitor of cholesterol biosynthesis, it inhibits the Δ7-sterol reductase with an IC50 of 13 nM. It can be used in the research to study Smith–Lemli–Opitz syndrome, a frequent inborn disorder of sterol metabolism.

TASIN-30 is a selective inhibitor of Emopamil binding protein (EBP) with EC50 values of 0.097 μM for EBP competition, respectively. TASIN-30 displays selectivity for EBP over DHCR24.